Symposium 12: People with type 2 diabetes treated with insulin: evidence to associate non-insulin drugs.
DOI:
https://doi.org/10.47196/diab.v56i3Sup.578Keywords:
diabetes mellitus, drugsAbstract
Diabetes is one of the fastest growing diseases all over the world. However, the current therapeutic strategies have not been able to stop neither its progressive course nor its complications. One possible explanation might be that the diabetes diagnosis is carried out according to glucose values, but the disease is heterogeneous regarding its causes, clinic presentation and evolution.
Diabetes historic classification in type 1 and type 2 is based, primarily, on the presence (type 1) or absebce (type 2) of autobodies against ß cells in the pancreatic islets. Therefore, 75-85% of the patients are classified as type 2 diabetes.
References
I. Ahlqvist E, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018 May;6(5):361-369.
II. Chubb B, et al. Once-daily oral semaglutide vs injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: Systematic Review and Network Meta-analysis. Diabetes Ther 2021 May;12(5):1325-1339.
III. Shibuki K, Shimada S, Aoyama T. Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin. Diabetes Metab Syndr 2022 Apr;16(4):102474.
IV. Ahmann A. Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. Drugs Context 2015 Nov 11;4:212288.
V. Wu B, et al. Effects of sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta-analysis of randomized controlled trials. J Diabetes Investig. 2019 Mar;10(2):446-457.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
